Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

Statins and Mortality in Connective Tissue Diseases: Should We Resume the Cardio-rheumatology Spirit in Our Clinics?

Gremese E, DE Lorenzis E, Ferraccioli GF.

J Rheumatol. 2018 Dec;45(12):1617-1619. doi: 10.3899/jrheum.180732. No abstract available.

PMID:
30504479
2.

Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus.

Caporali R, Doria A, Ferraccioli GF, Meroni PL, Zavaglia D, Iannone F.

Biomed Res Int. 2018 Sep 9;2018:3878953. doi: 10.1155/2018/3878953. eCollection 2018.

3.

Preserved cardiorespiratory function and NT-proBNP levels before and during exercise in patients with recent onset of rheumatoid arthritis: the clinical challenge of stratifying the patient cardiovascular risks.

Zoli A, Bosello S, Comerci G, Galiano N, Forni A, Loperfido F, Ferraccioli GF.

Rheumatol Int. 2017 Jan;37(1):13-19. doi: 10.1007/s00296-015-3390-2. Epub 2015 Nov 19.

PMID:
26586235
4.

Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.

Simone D, Nowik M, Gremese E, Ferraccioli GF.

J Rheumatol Suppl. 2015 Nov;93:65-9. doi: 10.3899/jrheum.150640. Review.

PMID:
26523061
5.

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.

Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H.

Ann Rheum Dis. 2015 May;74(5):843-50. doi: 10.1136/annrheumdis-2013-204632. Epub 2014 Jan 15.

6.

Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.

Lapadula G, Ferraccioli GF.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S102-6. Epub 2012 Oct 18.

PMID:
23078880
7.

Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein.

Laria A, Zoli A, Bocci M, Castri F, Federico F, Ferraccioli GF.

Clin Rheumatol. 2012 Sep;31(9):1389-93. doi: 10.1007/s10067-012-2031-3. Epub 2012 Jul 22. Review.

PMID:
22820967
8.

Preliminary classification criteria for the cryoglobulinaemic vasculitis.

De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, De Marchi G, Ramos Casals M, Voulgarelis M, Lenzi M, Saccardo F, Fraticelli P, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Mazzaro C, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M.

Ann Rheum Dis. 2011 Jul;70(7):1183-90. doi: 10.1136/ard.2011.150755. Epub 2011 May 13.

9.
10.

Mycophenolic acid in rheumatology: mechanisms of action and severe adverse events.

Zizzo G, De Santis M, Ferraccioli GF.

Reumatismo. 2010 Apr-Jun;62(2):91-100. Review.

11.

[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"].

De Leonardis F, Alivernini S, Bonacci E, Buono AM, Bombardieri S, Ferraccioli GF, Montecucco C, Sinigaglia L, Trotta F, Valentini G.

Reumatismo. 2010 Jan-Mar;62(1):34-45. Italian.

12.

Physical training effects in renal transplant recipients.

Romano G, Simonella R, Falleti E, Bortolotti N, Deiuri E, Antonutto G, De Vita S, Ferraccioli GF, Montanaro D.

Clin Transplant. 2010 Jul-Aug;24(4):510-4. doi: 10.1111/j.1399-0012.2009.01098.x.

PMID:
19788449
13.

Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome.

Pietrapertosa D, Salaffi F, Peluso G, Bosello SL, Fedele AL, Cuoghi I, Michelutti A, Gremese E, Ferraccioli GF.

Rheumatology (Oxford). 2009 Oct;48(10):1242-6. doi: 10.1093/rheumatology/kep217. Epub 2009 Jul 27.

PMID:
19635732
14.

Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases.

Faustini F, Zoli A, Ferraccioli GF.

Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:1-9. Review.

PMID:
19530505
15.

Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis.

Ria F, Penitente R, De Santis M, Nicolò C, Di Sante G, Orsini M, Arzani D, Fattorossi A, Battaglia A, Ferraccioli GF.

Arthritis Res Ther. 2008;10(6):R135. doi: 10.1186/ar2553. Epub 2008 Nov 17.

16.

Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis.

Tolusso B, Frezza D, Mattioli C, Fedele AL, Bosello S, Faustini F, Peluso G, Giambra V, Pietrapertosa D, Morelli A, Gremese E, De Santis M, Ferraccioli GF.

Ann Rheum Dis. 2009 Mar;68(3):416-9. doi: 10.1136/ard.2008.095414. Epub 2008 Oct 24.

17.

A paraneoplastic retroperitoneal fibrosis resistant to corticosteroids treated with tamoxifen.

Costanzi S, Zoli A, Ferraro PM, Danza FM, Ferraccioli GF.

Clin Nephrol. 2008 Aug;70(2):172-5.

PMID:
18793535
18.

Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.

Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.

Nephrol Dial Transplant. 2009 Jan;24(1):156-60. doi: 10.1093/ndt/gfn454. Epub 2008 Aug 6.

PMID:
18685141
19.

Induction and protection of autoimmune rheumatic diseases. The role of infections.

Cooke A, Ferraccioli GF, Herrmann M, Romani L, Schulze C, Zampieri S, Doria A.

Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S1-7. Review.

PMID:
18570747
20.

General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus.

Tomietto P, Annese V, D'agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF.

Arthritis Rheum. 2007 Dec 15;57(8):1461-72.

Supplemental Content

Loading ...
Support Center